Omvoh vs Stelara for Ulcerative Colitis: Patient Guide

Omvoh and Stelara both target IL-23 pathway inflammation in moderate-to-severe ulcerative colitis, but with different mechanism specificity and clinical profiles. Stelara is an IL-12/23 p40 biologic approved for UC in October 2019 based on UNIFI. Omvoh is an IL-23 p19-selective biologic approved for UC in October 2023 based on LUCENT-1 and LUCENT-2. Patients choosing between these two non-anti-TNF IL-23 pathway drugs often weigh mechanism specificity, urgency outcomes, and long-term dosing. This guide walks through the omvoh vs stelara ulcerative colitis decision.

IL-12/23 p40 vs IL-23 p19

Stelara (ustekinumab) binds the p40 subunit shared by IL-12 and IL-23, blocking both cytokines. Omvoh (mirikizumab) binds the p19 subunit unique to IL-23, selectively blocking IL-23 while leaving IL-12 signaling intact. Preserving IL-12 is theorized to maintain certain immune surveillance functions that p40 blockade disrupts. The mirikizumab vs ustekinumab UC distinction shapes how each drug performs on different UC endpoints, particularly bowel urgency and endoscopic remission.

UC Efficacy Data

Stelara's UC efficacy rests on UNIFI, which showed clinical remission rates at week 8 significantly better than placebo, with sustained remission through week 44. Omvoh's UC efficacy comes from LUCENT-1 (induction) and LUCENT-2 (maintenance). LUCENT-1 showed clinical remission rates of 24.2% on Omvoh versus 13.3% on placebo at week 12, with endoscopic remission, symptomatic remission, and bowel urgency improvement also significantly better. LUCENT-2 showed 49.9% of mirikizumab patients in clinical remission at week 40 versus 25.1% on placebo. No head-to-head trial has directly compared Omvoh with Stelara in UC. Indirect comparisons suggest similar clinical remission rates, with Omvoh potentially offering more robust bowel urgency data.

Onset of Action

Both drugs produce clinically meaningful UC response around week 8 to 12. Stelara's onset is slightly earlier, with UNIFI showing benefit at the week 8 primary endpoint. Omvoh's LUCENT data used a week 12 induction endpoint. For UC patients weighing induction speed, the two drugs are comparable in practice, and individual response variability often matters more than the small difference in trial endpoints.

Bowel Urgency Outcomes

A distinctive feature of Omvoh's data is bowel urgency improvement, a patient-reported outcome often undertreated in UC. LUCENT showed significant improvement in urgency numerical rating scale scores at both induction and maintenance, which matters to patients whose daily life is disrupted by sudden urgency episodes. Stelara's UC program did not formally evaluate bowel urgency with the same rigor, though real-world data supports general symptom improvement on ustekinumab. For UC patients whose primary quality-of-life concern is urgency rather than stool frequency, Omvoh's outcome profile is distinctive.

Safety Profile

Both drugs have favorable safety profiles relative to anti-TNFs. Stelara's UC safety data is reassuring across more than a decade of post-marketing experience in psoriasis, Crohn's, and UC, with low rates of serious infection. Omvoh's UC safety data from LUCENT has been favorable, consistent with other IL-23 p19 biologics. For omvoh vs stelara side effects, both drugs represent attractive options for patients concerned about long-term infection risk on anti-TNFs. The theoretical advantage of preserving IL-12 with Omvoh has not translated into clearly differentiated safety outcomes in head-to-head trials, which do not exist yet.

Administration and Dosing

Stelara starts with weight-based IV induction at week 0 (dose 260-520 mg based on weight), followed by subcutaneous maintenance of 90 mg every 8 weeks, per Janssen's Stelara prescribing information. Omvoh uses IV induction at 300 mg every 4 weeks for three doses (weeks 0, 4, and 8), followed by subcutaneous maintenance at 200 mg every 4 weeks, per Lilly's Omvoh prescribing information. For UC patients comparing maintenance frequency, Stelara's every-8-week SC maintenance is less frequent than Omvoh's every-4-week SC maintenance. Induction burden differs: Stelara uses one IV infusion, while Omvoh uses three IV infusions.

Cost and Access

Stelara's patent expired in 2023, and ustekinumab biosimilars launched in the US market beginning in 2025, which may lower acquisition costs for Stelara going forward. Omvoh has no biosimilar and is priced as a branded biologic. For UC patients where insurance favors a lower-cost ustekinumab biosimilar, Stelara (or its biosimilar) may be the most accessible option. For patients whose plans cover Omvoh and who prioritize urgency outcomes or the IL-23 p19-selective mechanism, manufacturer copay assistance programs can help bridge cost gaps.

Choosing With Your GI

For a UC patient deciding between Omvoh and Stelara, both drugs offer meaningful advantages over anti-TNFs. Stelara tends to win on simpler single-dose IV induction, less frequent SC maintenance, biosimilar cost savings, and a longer post-marketing safety track record. Omvoh tends to win on distinctive bowel urgency outcomes from LUCENT and the IL-23 p19-selective mechanism that preserves IL-12 signaling. Ask your GI how response will be measured after induction, what to do if symptoms persist, and how your insurance handles ustekinumab biosimilars versus branded Omvoh. A log of stool frequency, urgency episodes, blood, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.